This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
by Sundeep Ganoria
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
by Kinjel Shah
NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.
5 Single-Stock ETFs That Doubled in a Month
by Sweta Killa
We have highlighted five single-stock ETFs that have doubled over the past month amid a historic Wall Street comeback.
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
by Kinjel Shah
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger
by Kinjel Shah
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement
by Zacks Equity Research
NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.
The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie
by Zacks Equity Research
Bayer, Novo Nordisk, GSK, Merck and AbbVie are part of the Zacks top Analyst Blog.
PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?
by Kinjel Shah
Both PFE and MRK have strong product and pipeline portfolios in oncology.
Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?
by Ahan Chakraborty
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals
by Kinjel Shah
Bayer reports first-quarter results. NVO and GSK announce licensing deals with smaller biotechs.
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?
by Sundeep Ganoria
While CRBP's pipeline shows promise, the company's lack of marketed products remains a concern.
ETFs to Capitalize on the Novo Nordisk-Septerna Deal
by Sweta Killa
Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
by Zacks Equity Research
SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
by Kinjel Shah
Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects.
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
by Zacks Equity Research
PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
by Kinjel Shah
NVO and JAZZ report first-quarter results. AZN's asthma study on Breztri meets key goals.
Novo Nordisk (NVO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Novo Nordisk (NVO) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.
Does Novo Nordisk (NVO) Have the Potential to Rally 51.24% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 51.2% upside potential for Novo Nordisk (NVO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up
by Zacks Equity Research
NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.
The Zacks Analyst Blog Highlights Novo Nordisk, Honeywell International and American Tower
by Zacks Equity Research
Novo Nordisk, Honeywell International and American Tower are part of the Zacks top Analyst Blog.
Top Analyst Reports for Novo Nordisk, Honeywell & American Tower
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Honeywell International Inc. (HON) and American Tower Corporation (AMT).
Why Novo Nordisk (NVO) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Inside Last Week's Wall Street Rally & Best-Performing ETF Areas
by Sanghamitra Saha
Wall Street soared last week as strong jobs data and easing trade tensions sparked market optimism.